Kate Therapeutics
Chelsey Tiger is a Senior Research Associate at Kate Therapeutics with experience in retroviral packaging and producer cell line generation. Prior to this role, Chelsey worked as a Research Associate III at Abintus Bio, Inc. focusing on retroviral packaging. Chelsey also has experience as a Molecular Biologist and Microbiologist in medical virology at the Texas Department of State Health Services. Additionally, Chelsey worked as a Research Microbiologist at Oklahoma State University studying Clostridium perfringens. Chelsey's educational background includes a Bachelor's Degree in Biological Sciences with a minor in Microbiology and Molecular Genetics from Oklahoma State University.
Kate Therapeutics
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.